Quarterly ResultAug 13, 2026, 04:18 PM
Alumis Q2 Net Loss $142.2M; Envudeucitinib PsO PASI 100 at 54%
AI Summary
Alumis Inc. reported a net loss of $142.2 million for Q2 2026, with revenue of $1.7 million. The company highlighted strong clinical results for envudeucitinib in plaque psoriasis, with 54% of patients achieving complete skin clearance (PASI 100) at 48 weeks in the ONWARD3 study, and remains on track for an FDA NDA submission in Q4 2026. Alumis also anticipates Phase 2b LUMUS topline data for envudeucitinib in SLE in Q3 2026 and plans to initiate a Phase 2 trial for A-005 in Parkinson's disease in 1H 2027. The company's cash position of $502.3 million is expected to fund operations into Q4 2027.
Key Highlights
- Envudeucitinib achieved 54% PASI 100 at 48 weeks in ONWARD3 PsO study.
- Alumis remains on track to submit NDA for envudeucitinib in PsO in Q4 2026.
- Anticipates potentially pivotal Phase 2b LUMUS topline data for envudeucitinib in SLE in Q3 2026.
- Plans to initiate Phase 2 biomarker trial for A-005 in Parkinson’s disease in 1H 2027.
- Reported Q2 2026 net loss of $142.2 million, compared to net income of $59.3 million in Q2 2025.
- Q2 2026 revenue was $1.7 million, down from $2.7 million in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $502.3 million as of June 30, 2026.
- Expects existing cash to fund operations into Q4 2027.
Price Impact
More from ALMS